260 related articles for article (PubMed ID: 9051872)
1. A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen.
Bjarnason I; Macpherson A; Rotman H; Schupp J; Hayllar J
Scand J Gastroenterol; 1997 Feb; 32(2):126-30. PubMed ID: 9051872
[TBL] [Abstract][Full Text] [Related]
2. Gastroduodenal tolerability of highly specific cyclo-oxygenase-2 inhibitor.
Hayllar J; Bjarnason I
Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():30-2. PubMed ID: 9032580
[TBL] [Abstract][Full Text] [Related]
3. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
[TBL] [Abstract][Full Text] [Related]
4. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
Laine L; Connors LG; Reicin A; Hawkey CJ; Burgos-Vargas R; Schnitzer TJ; Yu Q; Bombardier C
Gastroenterology; 2003 Feb; 124(2):288-92. PubMed ID: 12557133
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
Simon LS; Weaver AL; Graham DY; Kivitz AJ; Lipsky PE; Hubbard RC; Isakson PC; Verburg KM; Yu SS; Zhao WW; Geis GS
JAMA; 1999 Nov; 282(20):1921-8. PubMed ID: 10580457
[TBL] [Abstract][Full Text] [Related]
6. Effect of flosulide, a selective cyclooxygenase 2 inhibitor, on passive heymann nephritis in the rat.
Blume C; Heise G; Mühlfeld A; Bach D; Schrör K; Gerhardz CD; Grabensee B; Heering P
Kidney Int; 1999 Nov; 56(5):1770-8. PubMed ID: 10571785
[TBL] [Abstract][Full Text] [Related]
7. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.
Bensen WG; Fiechtner JJ; McMillen JI; Zhao WW; Yu SS; Woods EM; Hubbard RC; Isakson PC; Verburg KM; Geis GS
Mayo Clin Proc; 1999 Nov; 74(11):1095-105. PubMed ID: 10560596
[TBL] [Abstract][Full Text] [Related]
8. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Bensen WG; Zhao SZ; Burke TA; Zabinski RA; Makuch RW; Maurath CJ; Agrawal NM; Geis GS
J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327
[TBL] [Abstract][Full Text] [Related]
9. [Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid].
MMW Fortschr Med; 2004 Apr; 146(15):66. PubMed ID: 15373027
[No Abstract] [Full Text] [Related]
10. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis.
Lohmander LS; McKeith D; Svensson O; Malmenäs M; Bolin L; Kalla A; Genti G; Szechinski J; Ramos-Remus C;
Ann Rheum Dis; 2005 Mar; 64(3):449-56. PubMed ID: 15345500
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
Goldstein JL; Cryer B; Amer F; Hunt B
Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
[TBL] [Abstract][Full Text] [Related]
12. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo.
Harris SI; Kuss M; Hubbard RC; Goldstein JL
Clin Ther; 2001 Sep; 23(9):1422-8. PubMed ID: 11589257
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract.
Bjarnason I; Thjodleifsson B
Rheumatology (Oxford); 1999 May; 38 Suppl 1():24-32. PubMed ID: 10369403
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years.
Goldstein JL; Aisenberg J; Lanza F; Schwartz H; Sands GH; Berger MF; Pan S
Clin Ther; 2006 Mar; 28(3):340-51. PubMed ID: 16750449
[TBL] [Abstract][Full Text] [Related]
15. The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial.
Bias P; Buchner A; Klesser B; Laufer S
Am J Gastroenterol; 2004 Apr; 99(4):611-8. PubMed ID: 15089890
[TBL] [Abstract][Full Text] [Related]
16. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
Geis GS
Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen.
Makarowski W; Zhao WW; Bevirt T; Recker DP
Osteoarthritis Cartilage; 2002 Apr; 10(4):290-6. PubMed ID: 11950252
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen.
Shah AA; Thjodleifsson B; Murray FE; Kay E; Barry M; Sigthorsson G; Gudjonsson H; Oddsson E; Price AB; Fitzgerald DJ; Bjarnason I
Gut; 2001 Mar; 48(3):339-46. PubMed ID: 11171823
[TBL] [Abstract][Full Text] [Related]
19. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR; Sperling RS; Reicin A; Gertz BJ
Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
[TBL] [Abstract][Full Text] [Related]
20. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
